Rifapentine access in Europe: growing concerns over key tuberculosis treatment component (CROSBI ID 311298)
Prilog u časopisu | Pismo uredniku | međunarodna recenzija
Podaci o odgovornosti
Guglielmetti, Lorenzo ; Günther, Gunar ; Leu, Claude ; Cirillo, Daniela ; Duarte, Raquel ; Garcia-Basteiro, Alberto L. ; Goletti, Delia ; Janković, Mateja ; Kuksa, Liga ; Maurer, Florian P. ; Méchaï, Frédéric ; Tiberi, Simon ; van Leth, Frank ; Veziris, Nicolas ; Lange, Christoph
Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and the Tuberculosis Network European Trials group (TBnet
engleski
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination
rifapentine, tuberculosis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
59 (5)
2022.
2200388
3
objavljeno
0903-1936
1399-3003
10.1183/13993003.00388-2022
Povezanost rada
Kliničke medicinske znanosti